ORPHA:251325
Drug-induced vasculitis
Publications
648
81.8th percentile
Trials
0
Interventional, condition-specific
Researchers
1,058
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare secondary vasculitis characterized by inflammation of blood vessels caused by various drugs, including antibiotics, anti-tumor necrosis factor-alpha agents, immunotherapeutic drugs, and psychoactive agents, among others. The skin is most commonly affected, but other tissues and organs, such as the subcutis, kidneys, or lungs, may also be involved. Systemic disease develops only in a minority of patients, typically when treated with the causative drug over a prolonged period of time. Presenting signs and symptoms include skin rash, myalgia, arthralgia, fever, and malaise.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016664
- UMLS:C0340672
- NCIT:C112204
Additional Mondo synonyms (2)
drug induced cutaneous vasculitis · drug induced vasculitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
648 matched papers (434 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 198 for broader category vasculitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
648
648 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
648 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
434 in the last 10 years · high confidence · 81.8th percentile (publications denominator)
Phrase hits: 648 · MeSH hits: 0
Who's working on it?
1,058
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang J3 papers · 2025
Department of Dermatology, University of New Mexico, Albuquerque, New Mexico.
Papers in Europe PMC - 02Abbasi Z2 papers · 2022
Department of Internal medicine, Shahid Modarres Hospital, Shahid Beheshti university of medical sciences, Tehran, Iran
Papers in Europe PMC - 03Acharya I2 papers · 2025
Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA.
Papers in Europe PMC - 04Arend LJ2 papers · 2025
Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
Papers in Europe PMC - 05Baraldi O2 papers · 2024
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Papers in Europe PMC - 06Chen W2 papers · 2026
Department of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, Guangdong, China.
Papers in Europe PMC - 07Chen Y2 papers · 2026
Department of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, Guangdong, China.
Papers in Europe PMC - 08Dadkhahfar S2 papers · 2022
Skin research center, Shahid Beheshti university of medical sciences, Tehran, Iran
Papers in Europe PMC - 09Elwood H2 papers · 2022
Department of Dermatology, University of New Mexico, Albuquerque, New Mexico.
Papers in Europe PMC - 10Hekmat M2 papers · 2022
Department of cardiovascular surgery, Shahid Modarres Hospital, Shahid Beheshti university of medical sciences, Tehran, Iran
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial. 198 trials are registered for vasculitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
198 interventional trials matched vasculitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: vasculitis
198
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07033299·NOT YET RECRUITING·The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
Conditions: ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06983821·RECRUITING·Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
Conditions: Granulomatosis With Polyangiitis · Microscopic Polyangiitis (MPA)·Matched via name phrase
- NCT02939573·RECRUITING·A Randomized Multicenter Study for Isolated Skin Vasculitis
Conditions: Primary Cutaneous Vasculitis · Cutaneous Polyarteritis Nodosa · IgA Vasculitis · Henoch-Schönlein Purpura·Matched via name phrase
- NCT07212322·NOT YET RECRUITING·A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Idiopahic Inflammatory Myopathies · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Sjögren's Syndrome·Matched via name phrase
- NCT07315087·RECRUITING·CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Conditions: SLE - Systemic Lupus Erythematosus · SSc-Systemic Sclerosis · IIM- Idiopathic Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06794008·RECRUITING·BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Inflammatory Myopathy · Systemic Sclerosis (SSc) · ANCA-associated Vasculitis·Matched via name phrase
- NCT06986018·NOT YET RECRUITING·Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
Conditions: Idiopathic Inflammatory Myopathies · ANCA-Associated Vasculitis·Matched via name phrase
- NCT06611696·RECRUITING·Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06763783·ENROLLING BY INVITATION·Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
Conditions: Systemic Vasculitis · Spondylarthropathies · Psoriatic Arthritis · Scleroderma·Matched via name phrase
- NCT07490275·NOT YET RECRUITING·Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
Conditions: Refractory/Relapsed Systemic Lupus Erythematosus · Refractory / Relapsed / Progressive Systemic Sclerosis · Refractory / Relapsing / Progressive Inflammatory Myopathy · Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis·Matched via name phrase
- NCT06685042·RECRUITING·Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Conditions: Lupus Erythematosus, Systemic · System; Sclerosis · ANCA Associated Vasculitis · Dermatomyositis·Matched via name phrase
- NCT07339540·RECRUITING·the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Conditions: Recurrent or Refractory Systemic Lupus Erythematosus · Recurrent or Refractory IgG4 Related Diseases · Recurrent or Refractory Systemic Sclerosis · Recurrent or Refractory Idiopathic Inflammatory Myopathy·Matched via name phrase
- NCT06350110·RECRUITING·Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus · Lupus Nephritis · Autoimmune Diseases · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis·Matched via name phrase
- NCT06614270·RECRUITING·Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Conditions: Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV) · Idiopathic Inflammatory Myopathy (IIM) · Sjogren's Syndrome·Matched via name phrase
- NCT06676384·RECRUITING·Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Conditions: IgA Nephropathy · Renal Insufficiency, Chronic · IgA Vasculitis · IGA Glomerulonephritis·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT03004326·RECRUITING·Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Conditions: Cryoglobulinemic Vasculitis (CV) · Drug-induced Vasculitis · Eosinophilic Granulomatosis With Polyangiitis (EGPA) · IgA Vasculitis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 8 · after dedupe 8 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- isrctn·ISRCTN83474167·No longer recruiting·Phase II open-label trial of atezolizumab in patients with urinary tract squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22771691·No longer recruiting·A study to investigate if atezolizumab can reduce the size of urothelial cancer before surgery and to determine how the drug works
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17038127·No longer recruiting·A study investigating if a new medication, bintrafusp alfa, can reduce the size of urothelial carcinoma, a type of bladder cancer, before surgery to remove the bladder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11965217·No longer recruiting·A trial to assess whether the addition of atezolizumab to current standard treatment for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma, who are not able to have high dose therapy, improves survival outcomes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15354495·No longer recruiting·Randomised trial optimising COVID-19 vaccination in patients with chronic health conditions and a poor response to standard vaccination
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46576063·No longer recruiting·Tacrolimus monotherapy for uveitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN24461054·No longer recruiting·Health benefits from anti-viral therapy for mild chronic hepatitis C
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Drug-induced vasculitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Drug-induced vasculitis" OR "drug induced cutaneous vasculitis" OR "drug induced vasculitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Drug-induced vasculitis" OR "drug induced cutaneous vasculitis" OR "drug induced vasculitis"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"vasculitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:44:24.677Z
